SCHEMBL25756536

SCHEMBL25756536

Nc1nn(CC2CC2)c2ccn(CC(F)(F)F)c(=O)c12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K12 Q12852 1/20 0.34
GRM2 Q14416 7/20 0.33
LIPG Q9Y5X9 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAPT P10636 1/20 0.32
CNR2 P34972 1/20 0.31
PIK3CD O00329 2/20 0.31
PIK3CA P42336 2/20 0.31
PIK3CG P48736 2/20 0.31
PI4KA P42356 1/20 0.31
PI4KB Q9UBF8 1/20 0.31
CNR1 P21554 1/20 0.31
KMT2A Q03164 2/20 0.30
POLB P06746 1/20 0.30
ADORA2A P29274 1/20 0.30
PIK3CB P42338 1/20 0.30
PRKDC P78527 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14639387 0.62 FGFR1 (0.42) LMNAMAPTKMT2AMEN1
SCHEMBL13075504 0.60 ELANE (0.46) LIPGALDH1A1MAPTCNR1KMT2A
SCHEMBL11720724 0.59 FGFR1 (0.50) GRM2ALDH1A1LMNAMAPTPIK3CD
SCHEMBL9941511 0.59 MAPT (0.45) GRM2ALDH1A1LMNAL3MBTL1MAPT
SCHEMBL21960342 0.58 MAP3K14 (0.39) MAP3K12L3MBTL1MAPTPIK3CAKMT2A
SCHEMBL21961360 0.58 MAP3K14 (0.39) MAP3K12CNR2PIK3CACNR1PIK3CB
SCHEMBL28617167 0.58 RET (0.36) PIK3CDCNR1
SCHEMBL19903225 0.58 HTR2C (0.44) CNR2PIK3CDPIK3CAPIK3CGCNR1
SCHEMBL7952618 0.57 SMN1; SMN2 (0.42) ALDH1A1PIK3CDPIK3CAPIK3CGPI4KA
SCHEMBL1076952 0.57 GRM2 (0.54) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAP3K12 83/4885GRM2 1697/4885LIPG 3674/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAP3K12 83/4885GRM2 1697/4885LIPG 3674/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 MAP3K12 83/4885GRM2 1697/4885LIPG 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.